Aphaia Pharma Information

Aphaia Pharma is a clinical-stage biopharmaceutical company harnessing proprietary precision-targeted drug formulations to restore endogenous hormone release from nutrient-sensing cells in the gastrointestinal tract to treat and prevent metabolic disorders such as obesity and associated diseases. Aphaia’s lead drug candidate, an oral glucose formulation, has been shown to safely restore endogenous hormone release in individuals with obesity. It is being evaluated in two Phase 2 trials, one for chronic weight management in individuals with obesity and the second to improve glucose tolerance in individuals with prediabetes. The versatile design of Aphaia’s technology platform provides an opportunity for the development of treatments for multiple disease patterns.

Website	https://www.aphaiapharma.com/
Revenue	$2 million
Employees	12 (1 on RocketReach)
Founded	2018
Address	28 Bahnhofstrasse, Zug, Zug 6300, CH
Phone	+41 41 784 96 33
Technologies	JavaScript , HTML , Twitter +2 more (view full list)
Industry	Pharmaceutical Manufacturing, Manufacturing General, Other Healthcare Technology Systems, Manufacturing
Keywords	Biopharmaceutical, Biotechnology, Precision Medicine, Targeted Therapy, Clinical Stage, Pharmaceutical Research, Clinical Trials, Drug Development, Medical Research, Drug Formulation, Drug Delivery, Hormone Replacement, Health Technology, Preclinical Studies, Hormone Therapy, Gastrointestinal Health
Competitors	Amgen, Gilead Sciences, Biogen, Roche, Novartis, Pfizer, Merck & Co., Inc., AbbVie, Johnson & Johnson, AstraZeneca +43 more (view full list)
SIC	SIC Code 283 Companies, SIC Code 28 Companies
NAICS	NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies